Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorGuangzhou 8th People's Hospital
About this trial
Evaluate the potential of ART combined with interferon therapy to achieve functional cure of hepatitis B in HIV/HBV co-infected patients
Eligibility criteria
Qualifiers
Age 18-65 years old, gender unrestricted.
Meeting the People's Republic of China Health Industry Standard (WS293-2008) - "AIDS and HIV Infection Diagnostic Criteria", confirmed as HIV-1 infected.
HBsAg positive for more than 6 months.
At least 1 year of ART treatment prior to screening, and currently undergoing ART treatment with HBsAg <1000IU/mL, HBeAg negative, HBV DNA <100IU/ml, CD4+T lymphocyte count >200 cells/μL and HIV-RNA<20 copies/ml.
Disqualifiers
Pregnant, nursing, planning pregnancy, or with severe mental disorders or uncontrolled epilepsy.
Co-infected with Hepatitis A, C, D, or E viruses.
With other chronic liver diseases like autoimmune hepatitis, drug-induced hepatitis, alcoholic hepatitis, genetic metabolic liver diseases, or moderate to severe fatty liver.
With autoimmune diseases like rheumatoid arthritis, psoriasis, or lupus.
Trial design
Treatments tested in this trial
- Peginterferon alfa-2b Injection
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov